| Code | CSB-RA004929MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody KYS202002A, targeting CD38, a type II transmembrane glycoprotein with multiple enzymatic functions. CD38 serves as both an ectoenzyme that regulates calcium mobilization through NAD+ metabolism and as a receptor involved in cell adhesion and signal transduction. This multifunctional protein is expressed on various immune cells including plasma cells, activated T cells, and natural killer cells, playing critical roles in immune regulation and cellular metabolism. CD38 has emerged as an important therapeutic target in hematological malignancies, particularly multiple myeloma, where it is highly expressed on malignant plasma cells.
As a biosimilar to KYS202002A, this antibody provides researchers with a reliable tool for investigating CD38 biology and its role in cancer immunology. It supports studies examining plasma cell disorders, immune cell activation mechanisms, and potential therapeutic interventions. This reagent is valuable for researchers exploring CD38-mediated pathways in oncology, immunology, and metabolic research contexts.
There are currently no reviews for this product.